Hydroxocobalamin as a New and Possibly Superior Treatment for Refractory Vasoplegic Syndrome during Liver Transplant Surgery

Overview

About this study

The purpose of this study is to evaluate if Hydroxocobalamin may be a new and possibly superior treatment for refractory vasoplegic syndrome during liver transplant surgery.

 

 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.

Inclusion Criteria:

  • Age > or = 18 years old.
  • Patients scheduled to undergo liver transplantation.

Exclusion Criteria: 

  • Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency documented as a medical history.
  • Patients taking serotonergic drugs such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), and monoamine oxidase inhibitors (MAOIs).
  • Patients with allergy to methylene blue or hydroxocobalamin.

 

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Sher-Lu Pai, M.D.

Contact us for the latest status

Contact information:

Karina Hex CCRP

127or7838928

Hex.Karina@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available